MCF7 Whole Cell Lysate: sc-2206

MCF7 whole cell lysate is derived from the MCF7 cell line, a well-established model of human breast cancer used predominantly in cancer research to study estrogen receptor (ER) positive breast cancer. This lysate provides an extensive array of cellular proteins, making it indispensable for studying hormone-related signaling pathways and their roles in cell proliferation and survival. Scientists utilize MCF7 lysate to delve into the mechanisms by which estrogen influences gene expression and cell cycle regulation through the ER. This includes investigations into the effects of estrogen on the activation of downstream targets such as cyclin D1 and Bcl-2, which are vital for cell cycle progression and apoptosis inhibition, respectively. Additionally, the lysate is used to explore the crosstalk between estrogen receptor signaling and other pathways, such as the PI3K/Akt and MAPK pathways, which contribute to cell survival and growth. MCF7 cell lysate aids in the identification and characterization of co-regulatory proteins that modulate ER activity and the cellular response to hormonal therapies in a research context, focusing strictly on the molecular dynamics of ER-positive breast cancer. This research aids in understanding the basic mechanisms of hormone response in breast cancer cells.

MCF7 Whole Cell Lysate References:

1. Oestrogenic activity of parabens in MCF7 human breast cancer cells.  |  Byford, JR., et al. 2002. J Steroid Biochem Mol Biol. 80: 49-60. PMID: 11867263
2. Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells.  |  Mooney, LM., et al. 2002. Br J Cancer. 87: 909-17. PMID: 12373608
3. Reduced expression of the regulatory A subunit of serine/threonine protein phosphatase 2A in human breast cancer MCF-7 cells.  |  Suzuki, K. and Takahashi, K. 2003. Int J Oncol. 23: 1263-8. PMID: 14532964
4. Cobalt chloride-induced estrogen receptor alpha down-regulation involves hypoxia-inducible factor-1alpha in MCF-7 human breast cancer cells.  |  Cho, J., et al. 2005. Mol Endocrinol. 19: 1191-9. PMID: 15695373
5. Proteomic analysis of ubiquitinated proteins from human MCF-7 breast cancer cells by immunoaffinity purification and mass spectrometry.  |  Vasilescu, J., et al. 2005. J Proteome Res. 4: 2192-200. PMID: 16335966
6. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.  |  Macedo, LF., et al. 2006. Cancer Res. 66: 7775-82. PMID: 16885381
7. Effect of sulphation on the oestrogen agonist activity of the phytoestrogens genistein and daidzein in MCF-7 human breast cancer cells.  |  Pugazhendhi, D., et al. 2008. J Endocrinol. 197: 503-15. PMID: 18492816
8. Development of a bio-assay for estrogens using estrogen receptor alpha gene expression by MCF7 cells as biomarker.  |  Swart, JC. and Pool, EJ. 2009. J Immunoassay Immunochem. 30: 150-65. PMID: 19330641
9. Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.  |  Gerotziafas, GT., et al. 2012. Thromb Res. 129: 779-86. PMID: 21917301
10. A novel method to detect intracellular metabolite alterations in MCF-7 cells by doxorubicin induced cell death.  |  Kumar, A., et al. 2021. Metabolomics. 17: 3. PMID: 33389242
11. Depletion of HP1α alters the mechanical properties of MCF7 nuclei.  |  Pradhan, S., et al. 2021. Biophys J. 120: 2631-2643. PMID: 34087208
12. Location of BRCA1 in human breast and ovarian cancer cells.  |  Scully, R., et al. 1996. Science. 272: 123-6. PMID: 8600523
13. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.  |  Migliaccio, A., et al. 1996. EMBO J. 15: 1292-300. PMID: 8635462